Clinical Trial Update: OTO-413 in Subjects With Speech-in-Noise Hearing Impairment [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for OTO-413 in sensorineural hearing loss has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sensorineural Hearing Loss

Drugs mentioned

• OTO-413

Snippet

Sponsor: Otonomy, Inc. | Conditions: Sensorineural Hearing Loss | Phase 1, Phase 2 | Status: COMPLETED